Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Malignant Glioma: early-phase trial registry
11 of 41 indexed Malignant Glioma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #357 of 28,707 conditions by registered trial count.
41 US clinical trials · 11 currently recruiting · #357 of 28,707 conditions by registered trial count
Malignant Glioma: 41 US clinical trials tracked, 11 recruiting.
Malignant Glioma is the subject of 41 registered US clinical trials on ClinicalTrials.gov, 11 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 31 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 8 of these trials.
Enrollment posture brief
Registry condition malignant-glioma
OPEN 11 | RECR 27% | LATE 0 | EARLY 31 | RANK #357 | SPON 8
Volume-matched condition peers
Nearest open-share peer: Cancer Survivor (27% recruiting · 26 trials)
Malignant Glioma lists 11 open slots (27% of 41 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Malignant Glioma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Malignant Glioma is recruiting below its size-band peers.
11 of 41 indexed trials (26.8%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Malignant Glioma research.
National Cancer Institute (NCI) accounts for 8 of 41 trials (19.5%). 28 distinct sponsors appear on at least one study for this condition label.
-
Most Malignant Glioma trials plan to enrol fewer than 100 people.
Median target enrolment is 36 among the 41 trials that report a genuine target (sentinel values excluded). 35 of those (85.4%) plan for fewer than 100 participants.
-
Malignant Glioma research is mostly interventional.
37 interventional and 4 observational studies make up this index (90.2% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
41 total, page 1 of 1
A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)
National Cancer Institute (NCI)
NCT05099003
Mapping of Electrical Properties in the Brain
Mayo Clinic
NCT06470711
Serial Advanced Magnetic Resonance Imaging Scan for Guidance of Personalized Adaptive Radiotherapy for High Grade Glioma
M.D. Anderson Cancer Center
NCT04771806
Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery
Stanford University
NCT03510208
Non-invasive Glioma Characterization Through Molecular Imaging
University of Miami
NCT03684109
Preoperative Radiosurgery for the Treatment of High Grade Glioma, NeoGlioma Trial
Mayo Clinic
NCT05030298
CARv3-TEAM-E T Cells in Glioblastoma
Marcela V. Maus, M.D.,Ph.D.
NCT05660369
Immunotherapy Before and After Surgery for Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults
Sabine Mueller, MD, PhD
NCT04323046
Intratumoral Extracellular Metabolic Impact of DFMO and AMXT 1501 in Patients With Diffuse or High Grade Glioma
Mayo Clinic
NCT05717153
Fitness and Nutrition in Glioma
NYU Langone Health
NCT06665373
T2 Star Magnetic Resonance Imaging and Biomarker Blood Testing to Predict the Change and Progress of Malignant Gliomas
John M. Buatti
NCT07447531
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
National Cancer Institute (NCI)
NCT03155620
Optune for Children With High-Grade Glioma or Ependymoma, and Optune With Radiation Therapy for Children With DIPG
Children's Oncology Group
NCT03033992
BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas
University of California, San Francisco
NCT03749187
Mind-Body Intervention in Glioma Couples
M.D. Anderson Cancer Center
NCT03244995
Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma
National Cancer Institute (NCI)
NCT02359565
Nivolumab in Patients With IDH-Mutant Gliomas With and Without Hypermutator Phenotype
National Cancer Institute (NCI)
NCT03718767
Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma
National Cancer Institute (NCI)
NCT03919071
Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma
National Cancer Institute (NCI)
NCT04817254
Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations
National Cancer Institute (NCI)
NCT03581292
Simultaneous Multinuclear Metabolic MRI in Newly Diagnosed or Recurrent Glioma
Jonsson Comprehensive Cancer Center
NCT05045027
PEP-CMV in Recurrent MEdulloblastoma/Malignant Glioma
Daniel Landi
NCT03299309
Memory-Enriched T Cells in Treating Patients With Recurrent or Refractory Grade III-IV Glioma
City of Hope Medical Center
NCT03389230
A Pilot Study Using 18F-DOPA PET-guided Radiotherapy in Gliomas
Mayo Clinic
NCT02104310
D2C7-IT With Atezolizumab for Recurrent Gliomas
Darell Bigner
NCT04160494
Effect H2 Water on QoL of Patients Receiving Radiotherapy for High Grade Gliomas.
Stony Brook University
NCT04175301
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
Five Prime Therapeutics
NCT02526017
Ferumoxytol in Improving MR Imaging in Patients With High-Grade Brain Tumors or Cerebral Metastases
OHSU Knight Cancer Institute
NCT00103038
Bevacizumab Plus Irinotecan Plus Carboplatin for Recurrent Malignant Glioma (MG)
Annick Desjardins
NCT00953121
Prognostic Awareness and Patient-Physician Communication in Malignant Glioma
Memorial Sloan Kettering Cancer Center
NCT02023346
18F-DOPA-PET in Finding Tumors in Patients With Newly Diagnosed Gliomas Undergoing Radiation Therapy
Mayo Clinic
NCT01991977
An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.
BBB-Therapeutics B.V.
NCT01386580
Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas
Children's Oncology Group
NCT02323880
Tremelimumab and Durvalumab in Combination or Alone in Treating Patients With Recurrent Malignant Glioma
Northwestern University
NCT02794883
Antisense102: Pilot Immunotherapy for Newly Diagnosed Malignant Glioma
david andrews
NCT02507583
Hypofractionated Stereotactic Irradiation With Nivolumab, Ipilimumab and Bevacizumab in Patients With Recurrent High Grade Gliomas
H. Lee Moffitt Cancer Center and Research Institute
NCT02829931
Neo-adjuvant Evaluation of Glioma Lysate Vaccines in WHO Grade II Glioma
Jennie Taylor
NCT02549833
AZD8055 for Adults With Recurrent Gliomas
National Cancer Institute (NCI)
NCT01316809
Ribociclib and Everolimus in Treating Children With Recurrent or Refractory Malignant Brain Tumors
Pediatric Brain Tumor Consortium
NCT03387020
Vaccination-Dendritic Cells With Peptides for Recurrent Malignant Gliomas
Frank Lieberman
NCT00766753
Safety and Efficacy Study of REOLYSIN® in the Treatment of Recurrent Malignant Gliomas
Oncolytics Biotech
NCT00528684
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 22 |
| Phase 2 | 9 |
Top Sponsors
Named interventions
Most-linked intervention names on Malignant Glioma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Malignant Glioma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Malignant Glioma page
41 registered trials, 11 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 11 Malignant Glioma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Cancer Institute (NCI) sponsors the most Malignant Glioma trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Malignant Glioma condition card totals 41 registered trials; most-linked intervention Magnetic Resonance Imaging; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.